| nte:Jul. 20 <sup>th</sup> , 2021  |
|---|
| ur Name:Wei Gu  |
| anuscript Title: Echocardiographic Changes in Elderly Patients with Heart Failure with Reduced Ejection Fraction  |
| ter Sacubitril-Valsartan Treatment  |
| anuscript number (if known): CDT-21-355   |
| the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are lated to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third |
| rties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment  |
| transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a  |
| lationship/activity/interest, it is preferable that you do so.  |

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  |   |
|   |   | Time frame: past  | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None  |   |
| 3 | Royalties or licenses   | None  |   |
| 4 | Consulting fees   | None  |   |

| 5   | Payment or honoraria for        | None                           |             |   |
|-----|---------------------------------|--------------------------------|-------------|---|
|     | lectures, presentations,        |                                |             |   |
|     | speakers bureaus,               |                                |             |   |
|     | manuscript writing or           |                                |             |   |
|     | educational events              | None                           |             |   |
| 6   | Payment for expert testimony    | None                           |             | _ |
|     | testimony                       |                                |             | _ |
| 7   | Support for attending           | None                           |             |   |
| ,   | meetings and/or travel          | None                           |             |   |
|     |                                 |                                |             |   |
|     |                                 |                                |             |   |
| 8   | Patents planned, issued or      | None                           |             |   |
|     | pending                         |                                |             |   |
|     |                                 |                                |             |   |
| 9   | Participation on a Data         | None                           |             |   |
|     | Safety Monitoring Board or      |                                |             |   |
|     | Advisory Board                  |                                |             |   |
| 10  | Leadership or fiduciary role    | None                           |             |   |
|     | in other board, society,        |                                |             |   |
|     | committee or advocacy           |                                |             |   |
| 11  | group, paid or unpaid           | News                           |             | _ |
| 11  | Stock or stock options          | None                           |             |   |
|     |                                 |                                |             |   |
| 12  | Receipt of equipment,           | None                           |             |   |
| 12  | materials, drugs, medical       | NOTIE                          |             | _ |
|     | writing, gifts or other         |                                |             | _ |
|     | services                        |                                |             |   |
| 13  | Other financial or non-         | None                           |             | _ |
|     | financial interests             |                                |             |   |
|     |                                 |                                |             |   |
|     |                                 |                                |             |   |
| Ple | ease summarize the above co     | onflict of interest in the fol | lowing box: |   |
|     |                                 |                                |             |   |
|     | Wei Gu has nothing to disclose. |                                |             |   |
|     |                                 |                                |             |   |

| Date:Jul. 20 <sup>th</sup> , 2021   |
|---|
| our Name:Chuangye Xu  |
| Manuscript Title: Echocardiographic Changes in Elderly Patients with Heart Failure with Reduced Ejection Fraction |
| after Sacubitril-Valsartan Treatment  |
| Manuscript number (if known): CDT-21-355  |
|   |
|   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
|   |   |   | P. G  |
| 1 | All support for the present                             | None  |   |
|   | manuscript (e.g., funding,                              |   |   |
|   | provision of study materials,                           |   |   |
|   | medical writing, article                                |   |   |
|   | processing charges, etc.)  No time limit for this item. |   |   |
|   | No time limit for this item.                            |   |   |
|   |   |   |   |
|   |   |   |   |
|   |   | Time frame: past  | 36 months   |
| 2 | Grants or contracts from                                | None  |   |
|   | any entity (if not indicated                            |   |   |
|   | in item #1 above).                                      |   |   |
| 3 | Royalties or licenses                                   | None  |   |
|   |   |   |   |
|   |   |   |   |
| 4 | Consulting fees   | None  |   |

| 5   | Payment or honoraria for                           | None                          |              |   |
|-----|--|-------------------------------|--------------|---|
|     | lectures, presentations,                           |                               |              |   |
|     | speakers bureaus,                                  |                               |              |   |
|     | manuscript writing or educational events           |                               |              |   |
| 6   | Payment for expert                                 | None                          |              |   |
| O   | testimony  | None                          |              | _ |
|     | testimony  |                               |              |   |
| 7   | Support for attending                              | None                          |              |   |
| •   | meetings and/or travel                             |                               |              |   |
|     |  |                               |              | П |
|     |  |                               |              |   |
|     |  |                               |              |   |
| 8   | Patents planned, issued or                         | None                          |              |   |
| Ü   | pending  |                               |              |   |
|     | ponum <sub>o</sub>                                 |                               |              |   |
| _   | Doublein stien en e Dete                           | Nana                          |              | _ |
| 9   | Participation on a Data Safety Monitoring Board or | None                          |              |   |
|     | Advisory Board                                     |                               |              |   |
| 10  | Leadership or fiduciary role                       | None                          |              |   |
|     | in other board, society,                           |                               |              | _ |
|     | committee or advocacy                              |                               |              |   |
|     | group, paid or unpaid                              |                               |              |   |
| 11  | Stock or stock options                             | None                          |              |   |
|     | ·  |                               |              |   |
|     |  |                               |              |   |
| 12  | Receipt of equipment,                              | None                          |              |   |
|     | materials, drugs, medical                          |                               |              |   |
|     | writing, gifts or other                            |                               |              |   |
|     | services   |                               |              |   |
| 13  | Other financial or non-                            | None                          |              |   |
|     | financial interests                                |                               |              |   |
|     |  |                               |              |   |
|     |  |                               |              |   |
|     |  |                               |              |   |
| Ple | ease summarize the above c                         | onflict of interest in the fo | llowing box: |   |
| Г   |  |                               |              |   |
|     | Chuangye Xu has nothing to dis                     | sclose.                       |              |   |
|     |  |                               |              |   |

| Date:Jul. 20 <sup>th</sup> , 2021      |   |
|--|---|
| Your Name:Zhao Li                      |   |
| Manuscript Title: Echocardiographic Ch | hanges in Elderly Patients with Heart Failure with Reduced Ejection Fraction  |
| after Sacubitril-Valsartan Treatment   |   |
| Manuscript number (if known):          | CDT-21-355  |
|  | o disclose all relationships/activities/interests listed below that are Related" means any relation with for-profit or not-for-profit third |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  |   |
|   |   | Time frame: past  | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None  |   |
| 3 | Royalties or licenses   | None  |   |
| 4 | Consulting fees   | None  |   |

| 5   | Payment or honoraria for                     | None                          |             |   |
|-----|--|-------------------------------|-------------|---|
|     | lectures, presentations,                     |                               |             |   |
|     | speakers bureaus,                            |                               |             |   |
|     | manuscript writing or                        |                               |             |   |
|     | educational events                           |                               |             |   |
| 6   | Payment for expert                           | None                          |             |   |
|     | testimony                                    |                               |             |   |
|     |  |                               |             |   |
| 7   | Support for attending meetings and/or travel | None                          |             |   |
|     |  |                               |             |   |
|     |  |                               |             |   |
| 8   | Patents planned, issued or                   | None                          |             |   |
|     | pending                                      |                               |             |   |
|     |  |                               |             |   |
| 9   | Participation on a Data                      | None                          |             |   |
|     | Safety Monitoring Board or                   |                               |             |   |
|     | Advisory Board                               |                               |             |   |
| 10  | Leadership or fiduciary role                 | None                          |             |   |
|     | in other board, society,                     |                               |             |   |
|     | committee or advocacy                        |                               |             |   |
|     | group, paid or unpaid                        |                               |             |   |
| 11  | Stock or stock options                       | None                          |             |   |
|     |  |                               |             |   |
|     |  |                               |             |   |
| 12  | Receipt of equipment,                        | None                          |             | _ |
|     | materials, drugs, medical                    |                               |             | _ |
|     | writing, gifts or other                      |                               |             | _ |
|     | services                                     |                               |             |   |
| 13  | Other financial or non-                      | None                          |             |   |
| 13  | financial interests                          | ivorie                        |             |   |
|     | illialiciai liiterests                       |                               |             |   |
| Ple | ease summarize the above co                  | onflict of interest in the fo | lowing box: |   |
|     | Zhao Li has nothing to disclose.             |                               |             |   |

| Date:Jul. 20 <sup>th</sup> , 2021  |
|--|
| Your Name: Zhi-zhong Li  |
| Manuscript Title: Echocardiographic Changes in Elderly Patients with Heart Failure with Reduced Ejection Fraction    |
| after Sacubitril-Valsartan Treatment   |
| Manuscript number (if known): CDT-21-355   |
|  |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
|   |   | Time name. Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | None  |   |
|   |   | Time frame: past  | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | None  |   |
| 3 | Royalties or licenses   | None  |   |
| 4 | Consulting fees   | None  |   |

| 5   | Payment or honoraria for                              | None                          |               |   |
|-----|---|-------------------------------|---------------|---|
|     | lectures, presentations,                              |                               |               |   |
|     | speakers bureaus,<br>manuscript writing or            |                               |               |   |
|     | educational events                                    |                               |               |   |
| 6   | Payment for expert                                    | None                          |               |   |
|     | testimony   |                               |               | _ |
|     |   |                               |               | _ |
| 7   | Support for attending meetings and/or travel          | None                          |               |   |
|     |   |                               |               |   |
|     |   |                               |               |   |
| 8   | Patents planned, issued or                            | None                          |               |   |
|     | pending   |                               |               |   |
|     |   |                               |               |   |
| 9   | Participation on a Data                               | None                          |               |   |
|     | Safety Monitoring Board or                            |                               |               |   |
| 10  | Advisory Board  | Nene                          |               |   |
| 10  | Leadership or fiduciary role in other board, society, | None                          |               | _ |
|     | committee or advocacy                                 |                               |               | _ |
|     | group, paid or unpaid                                 |                               |               |   |
| 11  | Stock or stock options                                | None                          |               |   |
|     |   |                               |               |   |
|     |   |                               |               |   |
| 12  | Receipt of equipment,                                 | None                          |               |   |
|     | materials, drugs, medical                             |                               |               | _ |
|     | writing, gifts or other services                      |                               |               |   |
| 13  | Other financial or non-                               | None                          |               |   |
|     | financial interests                                   |                               |               |   |
|     |   |                               |               |   |
| Ple | ease summarize the above o                            | onflict of interest in the fo | ollowing box: |   |
|     | Zhi-zhong Li has nothing to disc                      | close.                        |               |   |
|     |   |                               |               |   |